These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1992569)

  • 41. Relapse on endocrine treatment in patients with stage D2 prostate cancer. Does second-line hormonal therapy affect survival?
    Matzkin H; Rangel MC; Soloway MS
    Urology; 1993 Feb; 41(2):144-8. PubMed ID: 8497986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controversies of androgen ablation therapy for metastatic prostate cancer.
    Wilson SS; Crawford ED
    Curr Pharm Des; 2006; 12(7):799-805. PubMed ID: 16515496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen deprivation therapy in locally advanced and metastatic prostate cancer.
    Ryan CJ; Small EJ
    Minerva Urol Nefrol; 2006 Sep; 58(3):119-26. PubMed ID: 17124482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing metastatic prostate cancer.
    Ngan S; Mazhar D; Waxman J
    Br J Hosp Med (Lond); 2005 Nov; 66(11):618-22. PubMed ID: 16308947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hormonal therapy for prostate cancer.
    Rosenberg AG; von Eschenbach AC
    Semin Surg Oncol; 1990; 6(2):71-6. PubMed ID: 2180044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.
    Toivanen R; Frydenberg M; Murphy D; Pedersen J; Ryan A; Pook D; Berman DM; ; Taylor RA; Risbridger GP
    Sci Transl Med; 2013 May; 5(187):187ra71. PubMed ID: 23720582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early versus delayed hormonal therapy in advanced prostate cancer.
    Mazeman E; Bertrand P
    Eur Urol; 1996; 30 Suppl 1():40-3; discussion 49. PubMed ID: 9072496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Castration-resistant prostate cancer: descriptive yet pejorative?
    Crawford ED; Petrylak D
    J Clin Oncol; 2010 Aug; 28(23):e408. PubMed ID: 20547989
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic options in treatment of advanced carcinoma of the prostate.
    Venner PM
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):73-7. PubMed ID: 2259929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How is androgen-dependent metastatic prostate cancer best treated?
    Robson M; Dawson N
    Hematol Oncol Clin North Am; 1996 Jun; 10(3):727-47. PubMed ID: 8773508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 52. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
    Azad AA; Jones EC; Chi KN
    Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
    [No Abstract]   [Full Text] [Related]  

  • 53. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.
    Smith JA
    J Urol; 1994 Jul; 152(1):132-4. PubMed ID: 8201642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen deprivation as primary treatment for early prostate cancer: should we "just do something"?
    Talcott JA
    J Natl Cancer Inst; 2002 Mar; 94(6):407-9. PubMed ID: 11904307
    [No Abstract]   [Full Text] [Related]  

  • 55. Ureteral obstruction from prostatic carcinoma: response to endocrine and radiation therapy.
    Michigan S; Catalona WJ
    J Urol; 1977 Nov; 118(5):733-8. PubMed ID: 916091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Natural history of metastasic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency].
    Rodriguez García N; Luján Galán M; Pascual Mateo C; García Tello AM; Torres Zambrano GM; Berenguer Sánchez A
    Actas Urol Esp; 2007; 31(7):714-8. PubMed ID: 17902463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate cancer. Endocrine and cytotoxic therapy.
    Smith PH
    Recent Results Cancer Res; 1981; 78():154-72. PubMed ID: 7022593
    [No Abstract]   [Full Text] [Related]  

  • 58. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy.
    Benson RC; Gorman PA; O'Brien PC; Holicky EL; Veneziale CM
    Cancer; 1987 May; 59(9):1599-606. PubMed ID: 3828960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary hormone therapy for locally advanced prostate cancer.
    Swanson GP
    Curr Urol Rep; 2006 May; 7(3):225-32. PubMed ID: 16630526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost and availability of therapeutic options in advanced prostatic carcinoma in Turkey.
    Ilker NY; Dillioğlugil O; Akdaş A
    Int Urol Nephrol; 1992; 24(2):155-7. PubMed ID: 1624259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.